← Back to Search

Antithrombotic Removal of Apixaban & Rivaroxaban for Bleeding (STAR-D Trial)

N/A

Waitlist Available

Led By Michael J Mack, MD

Research Sponsored by CytoSorbents, Inc

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through the first 48 hours post-operation

Awards & highlights

STAR-D Trial Summary

This trial will test a new method to reduce the risk of serious bleeding in patients taking blood thinners who need urgent surgery.

Eligible Conditions

Postoperative Hemorrhage
Blood Loss
Hemorrhage

STAR-D Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through the first day post-operation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through the first day post-operation

This trial's timeline: 3 weeks for screening, Varies for treatment, and through the first day post-operation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of perioperative bleeding

Secondary outcome measures

Chest tube drainage

DOAC drug removal: apixaban

DOAC drug removal: rivaroxaban

+7 more

STAR-D Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: DrugSorb-ATR InterventionExperimental Treatment1 Intervention

Standard of care + DrugSorb-ATR system

Group II: ControlPlacebo Group1 Intervention

Standard of care with Sham set-up

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

DrugSorb-ATR system

2021

N/A

~140

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

CytoSorbents, IncLead Sponsor

16 Previous Clinical Trials

4,516 Total Patients Enrolled

2 Trials studying Postoperative Hemorrhage

640 Patients Enrolled for Postoperative Hemorrhage

Michael J Mack, MDPrincipal InvestigatorBaylor Scott & White The Heart Hospital

2 Previous Clinical Trials

240 Total Patients Enrolled

1 Trials studying Postoperative Hemorrhage

140 Patients Enrolled for Postoperative Hemorrhage

C. M Gibson, MDPrincipal InvestigatorBeth Israel Deaconess Medical Center, The Baim Institute, and Harvard Medical School

1 Previous Clinical Trials

140 Total Patients Enrolled

1 Trials studying Postoperative Hemorrhage

140 Patients Enrolled for Postoperative Hemorrhage

Media Library

DrugSorb-ATR system Clinical Trial Eligibility Overview. Trial Name: NCT05093504 — N/A

DrugSorb-ATR system 2023 Treatment Timeline for Medical Study. Trial Name: NCT05093504 — N/A

Postoperative Hemorrhage Patient Testimony for trial: Trial Name: NCT05093504 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this clinical trial being conducted in numerous places across North America?

"This study is enrolling patients from 28 different sites, such as Bethesda North Hospital and TriHealth Inc. in Cincinnati. Additionally, the University of Colorado Denver and the University of Mississippi Jackson are also participating locations."

Answered by AI

Is enrollment in this clinical trial still available?

"The clinical trial in question, posted on December 27th 2021 and last modified on November 17th 2022, is not presently taking partakers. Nevertheless, there are 372 other medical studies that are currently recruiting patients."

Answered by AI